Twice-yearly dosing lets kids be kids

Actor Portrayals

Triptodur is administered as a single IM injection just once every 24 weeks1

Long-lasting LH suppression means fewer injections, giving kids time to be kids

No surgery required

Triptodur offers an improved administration experience1,2

In a clinical trial, local tolerance at the injection site immediately and
2 hours after the first and second triptorelin injections was judged to be very good

No known cases of firm or hardened abscess, flushing, or hyperhidrosis related to injection site reactions reported

Small 21G, 1.5 inch needle

Device designed using current technology to aid ease of use and safety for the administrator

In-person or live in-service support and training are available for administration. We will help your nurses feel confident administering Triptodur

Administering Triptodur

Watch: Reconstitution and Administration Instructions for Triptodur

View this step-by-step video for important instructions for the reconstitution and administration of Triptodur prior to injection.

Triptodur Administration Support

Triptodur Administration
Guide

For additional guidance on how to safely reconstitute and administer Triptodur, review the Triptodur Administration Booklet.

In-service Request Form

It is important that the healthcare provider administering Triptodur receives education regarding the specific reconstitution and administration instructions prior to an injection.

Complete this form to request Triptodur administration in-service support (virtual or live) from an Azurity representative.

IMPORTANT SAFETY INFORMATION FOR TRIPTODUR

INDICATION

TRIPTODUR is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP).

IMPORTANT SAFETY INFORMATION

Contraindications

TRIPTODUR is contraindicated in:

  • Individuals with a known hypersensitivity to triptorelin or any other component of the product, or other GnRH agonists or GnRH.
  • Women who are or may become pregnant. Expected hormonal changes that occur with TRIPTODUR treatment increase the risk for pregnancy loss and fetal harm when administered to a pregnant woman. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be advised of the potential risk to the fetus.

Warnings and Precautions

Initial Rise of Gonadotropins and Sex Steroid Levels – During the early phase of therapy, gonadotropins and sex steroids rise above baseline because of the initial stimulatory effect of the drug. Therefore, a transient increase in clinical signs and symptoms of puberty, including vaginal bleeding, may be observed during the first weeks of therapy or after subsequent doses.

Psychiatric Events – Psychiatric events have been reported in patients taking GnRH agonists. Postmarketing reports with this class of drugs include symptoms of emotional lability, such as crying, irritability, impatience, anger, and aggression. Monitor for development or worsening of psychiatric symptoms during treatment with TRIPTODUR.

Convulsions – Postmarketing reports of convulsions have been observed in patients receiving GnRH agonists, including triptorelin. These included patients with a history of seizures, epilepsy, cerebrovascular disorders, central nervous system anomalies or tumors, and patients on concomitant medications that have been associated with convulsions such as bupropion and SSRIs. Convulsions have also been reported in patients in the absence of any of the conditions mentioned above.

Pseudotumor Cerebri (idiopathic intracranial hypertension) – has been reported in pediatric patients receiving GnRH agonists, including triptorelin. Monitor patients for signs and symptoms of pseudotumor cerebri, including headache, papilledema, blurred vision, diplopia, loss of vision, pain behind the eye or pain with eye movement, tinnitus, dizziness, and nausea.

Adverse Reactions

In clinical trials for TRIPTODUR, the most common adverse reactions (≥4.5%) are injection site reactions, menstrual (vaginal) bleeding, hot flush, headache, cough, and infections (bronchitis, gastroenteritis, influenza, nasopharyngitis, otitis externa, pharyngitis, sinusitis, and upper respiratory tract infection).

To report SUSPECTED ADVERSE REACTIONS, contact Azurity Pharmaceuticals, Inc. at 1-800-461-7449, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

The Important Safety Information does not include all the information needed to use TRIPTODUR safely and effectively. For additional safety information, please consult the full Prescribing Information for TRIPTODUR.

References:

  1. Triptodur [package insert]. Woburn, MA: Azurity Pharmaceuticals, Inc; 2023.
  2. Klein K, Yang J, Aisenberg J, et al. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty. J Pediatr Endocrinol Metab. 2016;29(11):1241-1248.